LU91039I2 - Proteq flu et ses dérivés pharmaceutiquement acceptables - Google Patents
Proteq flu et ses dérivés pharmaceutiquement acceptablesInfo
- Publication number
- LU91039I2 LU91039I2 LU91039C LU91039C LU91039I2 LU 91039 I2 LU91039 I2 LU 91039I2 LU 91039 C LU91039 C LU 91039C LU 91039 C LU91039 C LU 91039C LU 91039 I2 LU91039 I2 LU 91039I2
- Authority
- LU
- Luxembourg
- Prior art keywords
- proteq
- flu
- pharmaceutically acceptable
- acceptable derivatives
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9071187A | 1987-08-28 | 1987-08-28 | |
US11033587A | 1987-10-20 | 1987-10-20 | |
US18605488A | 1988-04-25 | 1988-04-25 | |
US23439088A | 1988-08-23 | 1988-08-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
LU91039I2 true LU91039I2 (fr) | 2003-11-05 |
Family
ID=27492413
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LU90951C LU90951I2 (fr) | 1987-08-28 | 2002-09-04 | Eurifel rcp felv et ses dérivés pharmaceutiquement acceptables |
LU91039C LU91039I2 (fr) | 1987-08-28 | 2003-09-05 | Proteq flu et ses dérivés pharmaceutiquement acceptables |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LU90951C LU90951I2 (fr) | 1987-08-28 | 2002-09-04 | Eurifel rcp felv et ses dérivés pharmaceutiquement acceptables |
Country Status (17)
Country | Link |
---|---|
JP (3) | JP3348156B2 (fr) |
KR (1) | KR970011149B1 (fr) |
AR (1) | AR241939A1 (fr) |
AT (1) | AT408549B (fr) |
AU (2) | AU2427588A (fr) |
BE (1) | BE1002134A5 (fr) |
CH (2) | CH679934A5 (fr) |
DE (4) | DE10399031I1 (fr) |
DK (1) | DK175904B1 (fr) |
FR (1) | FR2621487B1 (fr) |
GB (1) | GB2217718B (fr) |
IL (1) | IL87581A0 (fr) |
IT (1) | IT1229484B (fr) |
LU (2) | LU90951I2 (fr) |
NL (4) | NL195051C (fr) |
NZ (1) | NZ225970A (fr) |
WO (1) | WO1989003429A1 (fr) |
Families Citing this family (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5338683A (en) * | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
US5505941A (en) * | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
DE10399031I1 (de) * | 1987-08-28 | 2004-01-29 | Health Research Inc | Rekombinante Viren. |
US5286639A (en) * | 1987-09-16 | 1994-02-15 | Nippon Zeon Co., Ltd. | Recombinant avipoxvirus |
DE3813093A1 (de) * | 1988-04-19 | 1989-11-09 | Immuno Ag | Rekombinantes plasmid, verfahren zum herstellen eines rekombinanten avipoxvirus, rekombinantes avipoxvirus und dessen verwendung |
US5631154A (en) * | 1988-06-10 | 1997-05-20 | Therion Biologics, Incorporated | Self assembled, defective, non-self-propagating lentivirus particles |
JP2538367B2 (ja) * | 1988-06-24 | 1996-09-25 | ブリティッシュ・テクノロジー・グループ・リミテッド | Fowlpoxウィルスの非必須領域 |
US5093258A (en) * | 1988-08-26 | 1992-03-03 | Therion Biologics Corporation | Recombinant fowlpox virus and recombination vector |
CA2001001A1 (fr) * | 1988-10-21 | 1990-04-21 | Matthew M. Binns | Promoteur du virus de l'acne molluscum |
US6248333B1 (en) | 1990-04-04 | 2001-06-19 | Health Research Inc. | Isolated nucleic acid sequence of equine herpesvirus type 1 glycoprotein D (EHV-1 gD) |
US5204243A (en) * | 1990-02-14 | 1993-04-20 | Health Research Incorporated | Recombinant poxvirus internal cores |
US5514375A (en) * | 1990-08-15 | 1996-05-07 | Virogenetics Corporation | Flavivirus recombinant poxvirus vaccine |
MY109299A (en) * | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
FR2668064B1 (fr) | 1990-10-23 | 1994-12-16 | Transgene Sa | Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne. |
US5756102A (en) * | 1990-11-20 | 1998-05-26 | Virogenetics Corporation | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants |
US6309647B1 (en) | 1999-07-15 | 2001-10-30 | Aventis Pasteur | Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants |
US5503834A (en) * | 1990-11-20 | 1996-04-02 | Virogenetics Corporation | Measles virus recombinant poxvirus vaccine |
IE68404B1 (en) * | 1990-11-20 | 1996-06-12 | Virogenetics Corp | Measles virus recombinant poxvirus vaccine |
US5759841A (en) * | 1990-11-20 | 1998-06-02 | Virogenetics Corporation | Immunological composition of measles virus utilizing recombinant poxvirus |
US5338679A (en) * | 1991-01-08 | 1994-08-16 | Her Majesty The Queen In Right Of Canada, As Represented By National Research Council Canada And Forestry Canada | Vertebrate poxvoris expression vector under the control of entomopoxvirus spheroidin gene promoter |
US5756101A (en) * | 1991-07-01 | 1998-05-26 | Pasteur Merieux Serums Et Vaccins | Malaria recombinant poxvirus |
EP0575491B1 (fr) * | 1991-03-07 | 2003-08-13 | Virogenetics Corporation | Souche de vaccin mise au point par genie genetique |
US5766597A (en) * | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Malaria recombinant poxviruses |
US5863542A (en) * | 1991-03-07 | 1999-01-26 | Virogenetics Corporation | Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts |
US5766598A (en) * | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products |
AU674491B2 (en) * | 1991-03-20 | 1997-01-02 | Virogenetics Corporation | Recombinant poxvirus malaria vaccine |
EP1156102A1 (fr) * | 1991-06-14 | 2001-11-21 | Virogenetics Corporation | Vaccin à base de poxvirus recombinant comprenant le virus de l'immunodéficience |
EP0597016A4 (en) * | 1991-07-26 | 1996-04-24 | Virogenetics Corp | Infectious bursal disease virus recombinant poxvirus vaccine. |
EP0538496B1 (fr) * | 1991-08-26 | 2003-10-29 | Baxter Healthcare S.A. | Virus de la variole aviaire recombinant comportant un gène FPV-tk intact |
US5443831A (en) * | 1991-10-29 | 1995-08-22 | University Of Delaware | Gene encoding glycoprotein B of Infectious Laryngotracheitis Virus |
US5869312A (en) * | 1992-01-13 | 1999-02-09 | Syntro Corporation | Recombinant swinepox virus |
US6497882B1 (en) | 1992-01-13 | 2002-12-24 | Syntro Corporation | Recombinant swinepox virus |
US6033904A (en) * | 1992-01-13 | 2000-03-07 | Syntro Corporation | Recombinant swinepox virus |
JP3706130B2 (ja) * | 1992-01-13 | 2005-10-12 | ヴァイロジェネティクス コーポレイション | マレック病ウイルス組換えポックスウイルスワクチン |
US6127163A (en) * | 1992-01-13 | 2000-10-03 | Syntro Corporation | Recombinant swinepox virus |
US6251403B1 (en) | 1992-01-13 | 2001-06-26 | Syntro Corporation | Recombinant swinepox virus |
US6328975B1 (en) | 1992-01-13 | 2001-12-11 | Syntro Corporation | Recombinant swinepox virus |
JPH08501452A (ja) * | 1992-09-21 | 1996-02-20 | ビアジーン,インコーポレイティド | Felv及び/又はfivに対する組換レトロウィルスベクター |
AU727278B2 (en) * | 1993-02-26 | 2000-12-07 | Syntro Corporation | Recombinant fowlpox viruses and uses thereof II |
US5925358A (en) * | 1993-02-26 | 1999-07-20 | Syntro Corporation | Recombinant fowlpox viruses and uses thereof |
CA2156423A1 (fr) * | 1993-02-26 | 1994-09-01 | Mark D. Cochran | Virus recombinants de molluscum contagiosum et leurs utilisations |
US6136318A (en) * | 1993-02-26 | 2000-10-24 | Cochran; Mark D. | Recombinant fowlpox viruses and uses thereof |
US5496731A (en) * | 1993-03-25 | 1996-03-05 | Xu; Hong-Ji | Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy |
US5843742A (en) * | 1994-12-16 | 1998-12-01 | Avigen Incorporated | Adeno-associated derived vector systems for gene delivery and integration into target cells |
EP0753581A1 (fr) | 1995-07-10 | 1997-01-15 | Immuno Ag | Virus recombinantes eucaryotes cytoplasmiques améliorés, un procédé pour leur préparation et leur utilisation comme vaccins |
US5858373A (en) * | 1995-12-01 | 1999-01-12 | Virogenetics Corporation | Recombinant poxvirus-feline infectious peritionitis virus, compositions thereof and methods for making and using them |
AU731860B2 (en) | 1996-07-25 | 2001-04-05 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Recombinant pox virus for immunization against tumor-associated antigens |
US6106825A (en) * | 1997-05-07 | 2000-08-22 | University Of Florida | Entomopoxvirus-vertebrate gene delivery vector and method |
WO1999007869A1 (fr) * | 1997-08-05 | 1999-02-18 | University Of Florida | Vaccin vivant recombinant comprenant un virus ne se repliquant pas ou se repliquant sans efficacite |
US6248582B1 (en) * | 1997-10-08 | 2001-06-19 | Imran Khan | Gene deleted recombinant FeLV proviral DNA for production of vaccines against FeLV |
JPH11165762A (ja) | 1997-12-01 | 1999-06-22 | Lintec Corp | チップ体搬送用カバーテープおよび封止構造体 |
US20020147143A1 (en) | 1998-03-18 | 2002-10-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US20030235557A1 (en) | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US6200560B1 (en) | 1998-10-20 | 2001-03-13 | Avigen, Inc. | Adeno-associated virus vectors for expression of factor VIII by target cells |
US6221349B1 (en) | 1998-10-20 | 2001-04-24 | Avigen, Inc. | Adeno-associated vectors for expression of factor VIII by target cells |
US7935805B1 (en) | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
US6602705B1 (en) | 1998-12-31 | 2003-08-05 | Chiron Corporation | Expression of HIV polypeptides and production of virus-like particles |
CA2374610A1 (fr) | 1999-06-28 | 2001-01-04 | Jordan J. N. Tang | Memapsine recombinante catalytiquement active et procedes d'utilisation |
KR100919916B1 (ko) | 2000-02-23 | 2009-10-07 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 종양 특이적 동물 단백질 |
EP1319069B1 (fr) | 2000-06-28 | 2008-05-21 | Corixa Corporation | Compositions et methodes pour le traitement et le diagnostic du cancer du poumon |
WO2002080982A2 (fr) | 2001-01-12 | 2002-10-17 | Chiron Corporation | Immunisation des muqueuses par acide nucleique |
ATE318321T1 (de) * | 2001-03-08 | 2006-03-15 | Akzo Nobel Nv | Leporipox-basierende vektorvakzine |
JP4499311B2 (ja) * | 2001-04-27 | 2010-07-07 | シャープ株式会社 | 放送受信端末 |
EP1515982A4 (fr) | 2001-05-09 | 2005-10-26 | Corixa Corp | Methodes et compositions pour la therapie et le diagnostic du cancer de la prostate |
US7211659B2 (en) | 2001-07-05 | 2007-05-01 | Chiron Corporation | Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof |
US20030198621A1 (en) | 2001-07-05 | 2003-10-23 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof |
DK1581119T3 (da) | 2001-12-17 | 2013-05-13 | Corixa Corp | Sammensætninger og fremgangsmåder til terapi og diagnose af inflammatoriske tarmsygdomme |
ZA200505302B (en) | 2003-01-06 | 2007-03-28 | Corixa Corp | Certain aminoalkyl glucosaminide phosphate compounds and their use |
US7960522B2 (en) | 2003-01-06 | 2011-06-14 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
CA2525825A1 (fr) | 2003-05-15 | 2005-01-27 | Chiron Corporation | Polynucleotides pour vih et polypeptides derives de botswana mj4 |
US7261882B2 (en) | 2003-06-23 | 2007-08-28 | Reagents Of The University Of Colorado | Methods for treating neuropathic pain by administering IL-10 polypeptides |
EP1804833A2 (fr) | 2004-09-22 | 2007-07-11 | GlaxoSmithKline Biologicals SA | Compositions immunogenes de staphylocoques |
AU2006335256B2 (en) | 2005-11-22 | 2012-10-18 | Novartis Vaccines And Diagnostics, Inc. | Norovirus and sapovirus antigens |
US20090081157A1 (en) | 2006-01-09 | 2009-03-26 | Richard Syd Kornbluth | Immunostimulatory Combinations for Vaccine Adjuvants |
US7842299B2 (en) | 2006-03-14 | 2010-11-30 | Oregon Health & Science University | Methods for producing an immune response to tuberculosis |
AU2008221383B2 (en) | 2007-02-28 | 2012-09-13 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Brachyury polypeptides and methods for use |
DK2215269T3 (en) | 2007-10-15 | 2018-03-19 | Admedus Vaccines Pty Ltd | CONSTRUCTION SYSTEM AND APPLICATIONS THEREOF |
US8691502B2 (en) | 2008-10-31 | 2014-04-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
WO2010078556A1 (fr) | 2009-01-05 | 2010-07-08 | Epitogenesis Inc. | Compositions adjuvantes et méthodes d'utilisation |
US8664183B2 (en) | 2009-02-27 | 2014-03-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | SPANX-B polypeptides and their use |
WO2011063263A2 (fr) | 2009-11-20 | 2011-05-26 | Oregon Health & Science University | Procédés de génération de réponse immunitaire à la tuberculose |
US20130052221A1 (en) | 2010-02-26 | 2013-02-28 | The Govt. of the U.S, as represented by The Sec. of The Dept. of Health and Human Services | Dna-protein vaccination protocols |
US9795658B2 (en) | 2010-04-20 | 2017-10-24 | Admedus Vaccines Pty Ltd | Expression system for modulating an immune response |
WO2012106281A2 (fr) | 2011-01-31 | 2012-08-09 | The General Hospital Corporation | Molécules trail multimodales et leurs utilisations en thérapies cellulaires |
WO2012151272A2 (fr) | 2011-05-02 | 2012-11-08 | Tremrx, Inc. | Vaccination avec des lymphocytes t à l'aide de vecteurs viraux par rupture épidermique mécanique |
CA2837651A1 (fr) | 2011-06-21 | 2012-12-27 | Oncofactor Corporation | Compositions et methodes pour la therapie et le diagnostic du cancer |
CN103717235A (zh) | 2011-06-24 | 2014-04-09 | 埃皮托吉尼西斯有限公司 | 作为抗原特异性免疫调节剂的包含选择的载体、维生素、单宁和类黄酮的组合的药物组合物 |
US20150004144A1 (en) | 2011-12-02 | 2015-01-01 | The General Hospital Corporation | Differentiation into brown adipocytes |
WO2014035474A1 (fr) | 2012-08-30 | 2014-03-06 | The General Hospital Corporation | Compositions et méthodes de traitement du cancer |
WO2014043535A1 (fr) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions destinées à traiter le cancer |
EP2895191B1 (fr) | 2012-09-14 | 2019-06-05 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Protéine brachyury, vecteurs adénoviraux codant pour la protéine brachyury, et leur utilisation |
EP2986310B1 (fr) | 2013-04-17 | 2020-08-05 | Genzyme Corporation | Compositions de traitement et de prévention de la dégénérescence maculaire |
CA2913155A1 (fr) | 2013-05-21 | 2014-11-27 | President And Fellows Of Harvard College | Compositions se liant a l'heme manipulees et leurs utilisations |
EP3068783B1 (fr) | 2013-11-15 | 2020-09-23 | The Board of Trustees of the Leland Stanford Junior University | Les agonistes de récepteur 2 d'hypocrétine pur l'utilisation dans le traitement d'une insuffisance cardiaque |
TWI687225B (zh) | 2014-02-06 | 2020-03-11 | 美商健臻公司 | 用於治療及預防黃斑部病變的組成物及方法 |
JP7095990B2 (ja) | 2014-09-18 | 2022-07-05 | シーダーズ-サイナイ メディカル センター | 線維症を治療するための組成物及び方法 |
WO2016154010A1 (fr) | 2015-03-20 | 2016-09-29 | Makidon Paul | Compositions immunogènes pour une utilisation en vaccination contre les bordetella |
WO2016168601A1 (fr) | 2015-04-17 | 2016-10-20 | Khalid Shah | Agents, systèmes et méthodes de traitement du cancer |
CN107708718B (zh) | 2015-04-22 | 2022-01-11 | 西达-赛奈医疗中心 | 用于治疗2型糖尿病的肠内递送的苦味寡肽 |
EP4276106A3 (fr) | 2015-05-13 | 2024-01-24 | The United States of America as represented by the Secretary of the Department of Health and Human Services | Methodes et compositions pour eliciter des reponses immune a base des constructs contenant des elements conservatives |
WO2016196366A1 (fr) | 2015-05-29 | 2016-12-08 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Extension de durée de vie réplicative dans des maladies de vieillissement prématuré à l'aide d'isoformes p53 |
EP3313863B1 (fr) | 2015-06-29 | 2020-12-23 | The Board of Trustees of the Leland Stanford Junior University | Constructions de fusion de degron et procédés de régulation de la production de protéine |
EP3386593A4 (fr) | 2015-12-09 | 2019-07-24 | Admedus Vaccines Pty Ltd | Composition immunomodulatrice pour le traitement |
WO2018018082A1 (fr) | 2016-07-26 | 2018-02-01 | The Australian National University | Compositions immunostimulantes et utilisations de celles-ci |
US10917454B1 (en) | 2019-08-01 | 2021-02-09 | Rohde & Schwarz Gmbh & Co. Kg | System and method for ATC voice quality assurance |
WO2023070072A1 (fr) | 2021-10-21 | 2023-04-27 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Leurres de facteur de transcription générés par rétro-éléments |
WO2023077147A2 (fr) | 2021-11-01 | 2023-05-04 | Pellis Therapeutics, Inc. | Vaccins à lymphocytes t pour patients présentant une immunité humorale réduite |
WO2023081756A1 (fr) | 2021-11-03 | 2023-05-11 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Édition précise du génome à l'aide de rétrons |
WO2023141602A2 (fr) | 2022-01-21 | 2023-07-27 | Renagade Therapeutics Management Inc. | Rétrons modifiés et méthodes d'utilisation |
WO2023183588A1 (fr) | 2022-03-25 | 2023-09-28 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Procédés d'évaluation de l'activité rétronique modifiée et leurs utilisations |
WO2023183589A1 (fr) | 2022-03-25 | 2023-09-28 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Édition génomique à fidélité de rt-adn et à rétrons |
WO2023183627A1 (fr) | 2022-03-25 | 2023-09-28 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Production d'adn transcrit inversé (adn-rt) au moyen d'une rétron transcriptase inverse à partir d'adn exogène |
WO2024020346A2 (fr) | 2022-07-18 | 2024-01-25 | Renagade Therapeutics Management Inc. | Composants d'édition génique, systèmes et procédés d'utilisation |
WO2024044673A1 (fr) | 2022-08-24 | 2024-02-29 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Éditeurs de rétron à double coupe pour insertions et délétions génomiques |
WO2024044723A1 (fr) | 2022-08-25 | 2024-02-29 | Renagade Therapeutics Management Inc. | Rétrons modifiés et méthodes d'utilisation |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK489481A (da) * | 1980-11-10 | 1982-05-11 | Searle & Co | Plasmidvektor og frmgangsmaade til fremstilling deraf |
US4603112A (en) * | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
AU570940B2 (en) * | 1982-11-30 | 1988-03-31 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Process for producing poxvirus recombinants for expression offoreign genes |
FR2563434B1 (fr) * | 1984-04-25 | 1986-07-25 | Transgene Sa | Vaccin contre la rage et procede pour sa preparation |
EP0190254A4 (fr) * | 1984-07-05 | 1987-03-09 | Genex Corp | Gene clone et son procede de preparation et d'utilisation. |
DD235669A1 (de) * | 1985-03-26 | 1986-05-14 | Akad Wissenschaften Ddr | Verfahren zur herstellung eines blv-kodierten huellproteins |
WO1986005806A1 (fr) * | 1985-03-29 | 1986-10-09 | National Research Development Corporation | Proteine "pointe" du virus de la bronchite infectieuse |
EP0213894A3 (fr) * | 1985-08-23 | 1987-10-21 | Advanced Genetics Research Institute | Vaccins à particules virales imparfaites et méthodes d'utilisation |
AU607399B2 (en) * | 1985-09-09 | 1991-03-07 | Cetus Corporation | Infectious recombinant virus vaccine for feline leukemia |
GR862412B (en) * | 1985-09-25 | 1987-01-23 | Oncogen | Vaccines and immuinoassays for acquired immune deficiency syndrome |
AU602875B2 (en) * | 1985-12-18 | 1990-11-01 | British Technology Group Limited | Newcastle disease virus gene clones |
WO1988002022A1 (fr) * | 1986-09-22 | 1988-03-24 | Commonwealth Scientific And Industrial Research Or | Virus de la variole recombinant |
AU8075787A (en) * | 1986-09-22 | 1988-04-07 | Australian National University, The | Recombinant poxviruses |
EP0261940A3 (fr) * | 1986-09-23 | 1989-07-05 | Applied Biotechnology, Inc. | Vaccins pseudorabiques et vecteurs d'ADN pour recombiner avec les poxvirus |
DE3853088T2 (de) * | 1987-03-27 | 1995-10-19 | Nippon Zeon Co | Rekombinantes Avipoxvirus. |
DE10399031I1 (de) * | 1987-08-28 | 2004-01-29 | Health Research Inc | Rekombinante Viren. |
GB8724885D0 (en) * | 1987-10-23 | 1987-11-25 | Binns M M | Fowlpox virus promotors |
FR2632863B2 (fr) * | 1987-10-29 | 1990-08-31 | Transgene Sa | Virus du fowlpox recombinant et vaccins derives de ces virus |
JP2538367B2 (ja) * | 1988-06-24 | 1996-09-25 | ブリティッシュ・テクノロジー・グループ・リミテッド | Fowlpoxウィルスの非必須領域 |
WO1990010693A1 (fr) * | 1989-03-08 | 1990-09-20 | Health Research, Inc. | Systeme de selection d'hotes de poxvirus de recombinaison |
BR9106879A (pt) * | 1990-09-25 | 1993-07-20 | Cantab Pharma Res | Virus mutuante nao retroviral,uso do mesmo,vacina e processo de manufaturar umvirus mutante |
-
1987
- 1987-08-24 DE DE2003199031 patent/DE10399031I1/de active Pending
- 1987-08-24 DE DE2003199032 patent/DE10399032I1/de active Pending
-
1988
- 1988-08-24 AT AT0900788A patent/AT408549B/de not_active IP Right Cessation
- 1988-08-24 CH CH1444/91A patent/CH679934A5/de not_active IP Right Cessation
- 1988-08-24 NL NL8820679A patent/NL195051C/nl not_active IP Right Cessation
- 1988-08-24 DE DE3890874A patent/DE3890874C5/de not_active Expired - Lifetime
- 1988-08-24 KR KR1019890700753A patent/KR970011149B1/ko not_active IP Right Cessation
- 1988-08-24 GB GB8908921A patent/GB2217718B/en not_active Expired - Lifetime
- 1988-08-24 DE DE2002199049 patent/DE10299049I1/de active Pending
- 1988-08-24 JP JP50771588A patent/JP3348156B2/ja not_active Expired - Lifetime
- 1988-08-24 WO PCT/US1988/002816 patent/WO1989003429A1/fr active Application Filing
- 1988-08-24 CH CH1652/89A patent/CH679933A5/de not_active IP Right Cessation
- 1988-08-24 AU AU24275/88A patent/AU2427588A/en not_active Abandoned
- 1988-08-28 IL IL87581A patent/IL87581A0/xx not_active IP Right Cessation
- 1988-08-29 NZ NZ225970A patent/NZ225970A/xx unknown
- 1988-08-29 FR FR888811334A patent/FR2621487B1/fr not_active Expired - Lifetime
- 1988-08-29 BE BE8800978A patent/BE1002134A5/fr not_active IP Right Cessation
- 1988-08-29 IT IT8821772A patent/IT1229484B/it active
- 1988-08-29 AR AR88311787A patent/AR241939A1/es active
-
1989
- 1989-04-27 DK DK198902036A patent/DK175904B1/da active Protection Beyond IP Right Term
-
1995
- 1995-04-05 AU AU16288/95A patent/AU690210B2/en not_active Expired
-
2001
- 2001-10-09 JP JP2001311076A patent/JP2002186494A/ja active Pending
-
2002
- 2002-03-15 JP JP2002071416A patent/JP3826055B2/ja not_active Expired - Lifetime
- 2002-09-04 LU LU90951C patent/LU90951I2/fr unknown
-
2003
- 2003-07-09 NL NL300130C patent/NL300130I2/nl unknown
- 2003-09-05 LU LU91039C patent/LU91039I2/fr unknown
- 2003-11-25 NL NL300139C patent/NL300139I1/nl unknown
- 2003-11-25 NL NL300138C patent/NL300138I2/nl unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LU91039I2 (fr) | Proteq flu et ses dérivés pharmaceutiquement acceptables | |
LU90829I2 (fr) | Tepoxalin-zubrin et ses d-riv-s pharmaceutiquement acceptables | |
LU90736I2 (fr) | Agenerase-amprenavir et ses d-riv-s pharmaceutiquement acceptables | |
LU88736I2 (fr) | Cefquinome et ses dérivés pharmaceutiquement acceptables (COBACTAN) | |
LU90219I2 (fr) | Tolcapone et ses dérivés pharmaceutiquement acceptables (TASMAR) | |
LU88750I2 (fr) | VENLAFAXINE et ses dérivés pharmaceutiquement acceptables | |
LU90769I2 (fr) | Capecitabine et ses d-riv-es pharmaceutiquement acceptables (xeloda) | |
LU90069I2 (fr) | Lercanidipine et ses sels et dérivés pharmaceutiquement acceptables (Zanidip) | |
LU90484I2 (fr) | Novorapid - insuline asparte et ses sels et derives pharmaceutiquement acceptables | |
LU90037I2 (fr) | Konakion et ses dérivés pharmaceutiquement acceptables | |
NL300136I2 (nl) | Farmacologisch actieve catecholderivaten en samenstellingen ervan. | |
FI955939A0 (fi) | Farmaseuttisesti aktiivisia CNS-yhdisteitä | |
LU91189I2 (fr) | Atazanavir sulphate et ses dérivés pharmaceutiquement acceptables (REYATAZ) | |
LU91197I2 (fr) | Azoxystrobin et folpel et leurs dérivés pharmaceutiquement acceptables (QUADRIS MAX). | |
LU91147I2 (fr) | Pemetrexed et ses sels pharmaceutiquement acceptables. | |
DK40788A (da) | Phenylsubstituerede purinonderivater | |
KR910700249A (ko) | 신규 치료학적 활성 화합물 및 그의 제조 방법 | |
DK514589A (da) | Serviet | |
LU91673I2 (fr) | "Dronédarone et ses dérivés pharmaceutiquement acceptables (MULTAQ)" | |
LU90844I2 (fr) | es Riamet et ses d-riv-s pharmaceutiquement acceptabl | |
LU88790I2 (fr) | Moxidectin et ses dérivés pharmaceutiquement acceptables | |
LU88843I2 (fr) | Ropivacaine et ses dérivés pharmaceutiquement acceptables (Naropine R) | |
TR24895A (tr) | PIRIMIDIN TüREVLERI,BUNLARIN ISTIHSAL EDILMESI VE KULLANILMASI | |
IT1217573B (it) | Benzammidi sostituite farmacologicamente attive | |
LU90110I2 (fr) | Penciclovir et ses dérivés pharmaceutiquement acceptables |